Best GLP-1 Telehealth Providers 2025

Brand-name medications like Wegovy, Ozempic, Mounjaro, and Zepbound are FDA-approved and manufactured by pharmaceutical companies (Novo Nordisk and Eli Lilly). They typically cost $1,000+ per month without insurance.

Compounded medications are custom-made by licensed compounding pharmacies using the same active ingredients (semaglutide or tirzepatide). They're not FDA-approved but are legal when made by accredited pharmacies. They cost $83-$299/month, making them much more affordable. The FDA allows compounding when brand-name drugs are in shortage.

Insurance coverage varies significantly. Most insurance plans do NOT cover compounded GLP-1 medications from telehealth providers. However, some may cover brand-name versions (Wegovy, Zepbound) if prescribed for weight loss with appropriate medical documentation.

A few telehealth providers like Sequence and Form Health offer insurance navigation support to help you get brand-name medications covered. For most people, paying cash for compounded versions ($83-$299/month) is more affordable than brand-name medications even with insurance.

Most patients notice reduced appetite within the first 1-2 weeks. Visible weight loss typically begins within 4-8 weeks, with the most significant results occurring between months 3-12.

On average, patients lose 15-20% of their body weight over 12-18 months. For example, a 200-pound person might lose 30-40 pounds over a year. Individual results vary based on starting weight, lifestyle changes, medication adherence, and other factors.

No, most patients find GLP-1 injections virtually painless. The needles are very thin (similar to insulin needles) and you inject into fatty tissue under the skin, typically in your abdomen, thigh, or upper arm.

The injection takes just seconds, and most providers include detailed video instructions. After the first few times, it becomes routine. If you have a strong aversion to needles, ask about the new oral GLP-1 options like Wegovy pills (available January 2026).

Clinical studies show that most patients regain a significant portion of their lost weight (approximately 2/3) within one year of stopping GLP-1 medications. Your appetite will gradually return to pre-treatment levels as the medication leaves your system.

This is why GLP-1 medications are considered a long-term treatment, similar to medications for high blood pressure or cholesterol. Many patients stay on a maintenance dose indefinitely. Discuss a long-term plan with your provider before starting treatment.

Look for these key safety indicators:

• • LegitScript Certification: The gold standard for telehealth verification
• • Licensed Providers: Doctors, NPs, or PAs licensed in your state
• • Accredited Pharmacies: 503A or 503B registered compounding pharmacies
• • HIPAA Compliance: Proper protection of your medical information
• • Transparent Pricing: Clear costs with no hidden fees
• • Real Reviews: Verified customer reviews on third-party sites

Providers like Remedy Meds, Orderly Meds, and Ro have LegitScript certification. Avoid providers that don't clearly identify their medical team or pharmacy partners.

Yes, you can switch providers, but there are some considerations. Most telehealth providers operate on monthly subscriptions that you can cancel. However, you'll need a new consultation with your new provider, and there may be a gap in treatment during the transition.

Before switching, verify that your new provider can prescribe the same medication and dosage you're currently taking. Some patients switch to save money or get better support. Just ensure you don't run out of medication during the transition, as stopping abruptly isn't recommended.

No, you don't need an existing prescription. Telehealth providers have their own licensed healthcare providers who will evaluate your eligibility through an online consultation. They'll review your medical history, current medications, and weight loss goals.

If you're already taking GLP-1 medications prescribed by your regular doctor, you can mention this during your consultation. The telehealth provider's doctor will decide whether to continue the prescription, but you're not required to have a referral or existing prescription to get started.

Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist. Clinical trials show an average weight loss of 15-17% of body weight over 68 weeks. It's been available longer and has extensive safety data.

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist. It works on two hormonal pathways instead of one, leading to slightly higher average weight loss of 20-22% of body weight. However, it may have a higher rate of side effects.

Both are effective and safe. Your provider will recommend one based on your medical history, weight loss goals, and how you tolerate the medication. Some patients try both to see which works better for them.

GLP-1 medications have been used for diabetes treatment for over 15 years, providing substantial long-term safety data. The most serious (but rare) risks include:

• • Pancreatitis (inflammation of the pancreas) - rare
• • Gallbladder problems - occurs in some patients with rapid weight loss
• • Thyroid tumors - only seen in animal studies, not confirmed in humans
• • Gastroparesis - slowed digestion that usually resolves after stopping

For most patients, the cardiovascular and metabolic benefits (reduced risk of heart disease, stroke, diabetes) outweigh the risks. Your provider will monitor you regularly and discontinue treatment if concerning symptoms develop.